NEWS: 公告在東京證券交易所JASDAQ標準市場新上市


RT 100:新興醫藥品的考察、市場預測 (2030年)

RT 100 - Emerging Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 959700
出版日期 按訂單生產 內容資訊 英文 50 Pages
商品交期: 10個工作天內
RT 100:新興醫藥品的考察、市場預測 (2030年) RT 100 - Emerging Drug Insight and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 50 Pages

RT-100是一種研究性基因治療產品,可在心臟導管插入過程中(通常類似於血管造影術的門診程序)直接注入心臟的動脈中。已經證明這種基因轉移方法可以安全有效地將AC6直接遞送至心肌細胞。編碼人類AC6的基因透過修飾的腺病毒載體傳遞,該載體能夠進入細胞但不能自體再生(Ad5.hAC6)。 AC6被心臟吸收,並已顯示在心肌細胞中持續存在。不像小分子藥物療法能減少對人體的需求,這種基因療法旨在改善整體心臟功能。

本報告提供美國,歐洲5個國家(德國,法國,義大利,西班牙,英國)以及日本的7個主要市場上 RT-100 詳細說明 (含作用機制,劑量,合成途徑,法規的里程碑的研究開發活動,及其他的開發活動),含SWOT分析,市場競爭企業,及其他新治療方法的未來市場評估。


第1章 醫藥品概要

  • 產品詳細內容
  • 作用機制
  • 投藥和管理
  • 研究開發活動
    • 臨床開發
    • 安全性和有效性
  • 其他開發活動

第2章 市場評估

  • 主要7個國家市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 義大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章 SWOT分析

第4章 分析師的見解

第5章 市場競爭企業

第6章 其他新的治療方法

第7章 附錄

第8章 報告購買選擇

Product Code: DIDM0051

"RT 100 - Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Heart failure in 7 Major Markets. A detailed picture of the RT 100 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Drug Summary:

RT-100 is an investigational gene therapy product that is infused during cardiac catheterization - a commonly performed outpatient procedure similar to an angiography - directly into the arteries that feed the heart. This method of gene transfer has been shown to safely and efficiently deliver AC6 directly to heart muscle cells. The gene encoding human AC6 is delivered via a modified adenovirus vector that is able to enter the cells but cannot reproduce itself (Ad5.hAC6). The AC6 is taken in by the heart and has been shown to persist in heart muscle cells. Unlike small molecule drug treatments, which work to decrease demands on the body, this gene therapy is aimed at improving overall heart function. Rather than slow progression or minimize symptoms of CHF, RT-100 has the potential to halt and reverse the CHF-induced remodeling of the heart, enabling it to pump more effectively. Granted Fast Track designation by the U.S. Food and Drug Administration (FDA), RT-100 is in late-stage clinical development.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around RT 100.
  • The report contains forecasted sales for RT 100 till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) for Heart failure.
  • The report also features the SWOT analysis with analyst insights and key findings of RT 100.


The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

RT 100 Analytical Perspective by DelveInsight

In-depth RT 100 Market Assessment

This report provides a detailed market assessment of RT 100 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

RT 100 Clinical Assessment

The report provides the clinical trials information of RT 100 covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Heart failure is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence RT 100 dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Heart failure are giving market competition to RT 100 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of RT 100.
  • Our in-depth analysis of the forecasted sales data of RT 100 from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the RT 100.

Key Questions:

  • Which company is developing RT 100 along with the phase of the clinical study?
  • What is the technology utilized in the development of RT 100?
  • What is the product type, route of administration and mechanism of action of RT 100?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the RT 100 development?
  • What are the key designations that have been granted to RT 100?
  • What is the forecasted market scenario of RT 100?
  • What is the history of RT 100 and what is its future?
  • What is the forecasted sales of RT 100 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to RT 100?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 RT 100, Description
  • Table 2 RT 100, Clinical Trial Description
  • Table 3 RT 100, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of RT 100
  • Figure 2 Patent Details, RT 100
  • Figure 3 RT 100, 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 RT 100, US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 RT 100, EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 RT 100, Japan Market Size from 2020 to 2030 (in Millions USD)